Cataract　is　a　leading　cause　of　irreversible　vision　loss,　particularly　among　the　elderly,　with　drug-induced　cataract　being　an　underrecognized　yet　significant　contributor　to　visual　impairment.　This　study　investigates　the　associations　between　medications　and　cataract　development　using　real-world　data　from　the　FDA　Adverse　Event　Reporting　System　(FAERS)　from　Q1　2004　to　Q3　2024.　A　total　of　54,800　reports　were　analyzed,　including　2,336　cases　involving　691　drugs　in　individuals　aged　0-45　years.　Disproportionality　analysis　identified　24　drugs　significantly　associated　with　cataract　risk,　with　the　highest　risks　linked　to　glucocorticoids　(e.g.,　fluticasone　furoate,　triamcinolone),　insulin　analogs　(e.g.,　insulin　glargine,　insulin　human),　and　other　agents　like　nitisinone　and　ranibizumab.　Difluprednate　showed　the　strongest　association　(Bayesian　Confidence　Propagation　Neural　Network　[BCPNN]　=　7.83),　followed　by　prednisolone　(BCPNN　=　6.84)　and　erdafitinib　(BCPNN　=　5.44).　Difluprednate　had　the　shortest　median　onset　time　(74　days),　while　prednisolone＇s　median　onset　was　141　days.　Antineoplastic　agents　demonstrated　the　fastest　average　onset　of　cataracts　(533.89　days).　The　majority　of　cases　were　reported　in　females　(57.9%),　with　a　noticeable　annual　increase　in　cases.　This　study　provides　a　comprehensive　pharmacovigilance　evaluation,　offering　insights　into　high-risk　medications,　their　onset　patterns,　and　demographic　trends,　contributing　to　improved　clinical　decision-making　and　cataract　prevention　strategies.